Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212034 | 1.00 | LIPE (0.53) | LIPES1PR5ERN1MRGPRX4ENPP2 | |
| SCHEMBL16034064 | 0.88 | LIPE (0.53) | LIPES1PR5MRGPRX4ENPP2NPC1 | |
| SCHEMBL18500353 | 0.87 | ERN1 (0.41) | LIPES1PR5ERN1MRGPRX4ENPP2 | |
| SCHEMBL16320521 | 0.85 | LIPE (0.57) | LIPEENPP2NPC1FOLH1 | |
| SCHEMBL28606699 | 0.83 | LIPE (0.68) | LIPEENPP2NPC1FOLH1 | |
| SCHEMBL29954144 | 0.81 | LIPE (0.57) | LIPEMRGPRX4ENPP2 | |
| SCHEMBL8453 | 0.81 | ENPP2 (0.66) | LIPEMRGPRX4ENPP2NPC1 | |
| SCHEMBL29952431 | 0.81 | ENPP2 (0.66) | LIPEMRGPRX4ENPP2NPC1 | |
| SCHEMBL1163386 | 0.81 | LIPE (0.57) | LIPEMRGPRX4ENPP2 | |
| SCHEMBL17236436 | 0.81 | RAB9A (0.56) | LIPEENPP2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-113861188-B | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2023-02-28 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | LIPE 155/4885S1PR5 764/4885ERN1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.